About us
Chevalier Capital is exclusively a specialist M&A and Equity Advisor.
It is headquartered in Sydney and operates in the Asia-Pacific. Its team has extensive experience in cross-border transactions between Australia, Asia, Europe and the United States.
Chevalier Capital holds trusted senior relationships with and access to Australia’s leading boardrooms, Chairs and CEOs as well as to market-leading financial sponsors, family offices and principal investors.
Delivering for our clients is our number-one focus. It has been essential to our success. As an independent corporate finance house we chose to be free from any competing interests from stockbroking, lending or funds management businesses.
Chevalier Capital was exclusive financial adviser to the sale of PRP Diagnostic Imaging Holdings Limited (PRP) to Crescent Capital for $440 Mln on 30 June 2020. PRP is one of the five largest radiology groups in Australia by revenue. It’s 900 employees, including 90 doctors, provide 1 million patient examinations annually. PRP’s sale was the first major healthcare sale completed in the 2020 calendar year.
Most recently, Chevalier Capital was also exclusive financial adviser to the sale of Canberra Imaging Group (CIG) to Sonic Healthcare, announced on 17 June 2021. CIG, with annual revenues of ~A$60 million, is the largest radiology practice in Canberra, Australia’s capital city and fastest growing economy, with branches also located in Queanbeyan and Goulburn. The practice, with a history going back over 50 years, employs 15 radiologists and 200 other staff in 10 service locations. The sale of CIG was followed by the sale of the related healthcare properties (Properties) held by ACT X-Ray Service Trust and Specserve Trust in August 2022.